Effects of TRF on Obese Patients With CKD Stage 3-4

Guangdong Provincial Hospital of Traditional Chinese Medicine28 enrolled

Overview

Obesity is associated with glomerular hyperfiltration leading to renal impairment and is a risk factor for the progression of kidney disease.Weight loss can reduce proteinuria and improve eGFR.Intermittent fasting is safe and effective, and in addition to improving body shape and weight in obese patients, it can also improve glucolipid metabolism, reduce proteinuria, improve kidney function and delay the progression of kidney disease.

KDOQI clinical practice guideline for nutrition in chronic kidney disease (CKD) uses a low-protein diet to reduce renal impairment and delay progression. The current research hotspot is dietary intervention. Time-restricted feeding was used to intervene in the progression of CKD. It restrict the time of eating but not the eaten calories, which have a higher compliance and safety. Studies have shown that intermittent fasting in obese patients with CKD is not only reduce body weight, but also improves glycolipid metabolism, reduces proteinuria and delays the progression of kidney disease. Intermittent fasting is currently a scientific research hotspot, and there are few international studies on the implementation of intermittent fasting to delay the deterioration of renal function in obese CKD patients, and lack of data on Chinese patients, which has great research potential. Based on the above background, this study was conducted as an pilot clinical trial to explore the effects of intermittent fasting on obese patients with CKD and to observe its effectiveness, safety and compliance.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Time Restricted Feeding Renal Insufficiency, Chronic Obesity

Interventions

Time-restricted feeding(TRF)BEHAVIORAL

The TRF group was asked to restrict the eating window to 8 hours a day, during waking hours and also continue a low-protein diet.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-65 years * CKD stage 3-4 and not on dialysis (eGFR: 15-59ml/min/1.73m2) * BMI ≥ 25 kg/m2 * Good reading and comprehension skills, simple smartphone operation and no communication difficulties * Signed informed consent Exclusion Criteria: * Pregnant and breastfeeding * End-stage diseases * Acute and active diseases such as gastrointestinal bleeding or acute infections, serious decompensation with diseases such as cirrhosis decompensation stage, malignant tumor, serious heart and lung diseases, severe primary diseases of hematopoietic system, severe hypertension (systolic blood pressure ≥200mmHg, diastolic blood pressure ≥120mmHg) and difficult to control blood pressure, within 3 months after major surgery, such as open surgery * Mental patients * Using medium-high doses of hormones and immunosuppressants * Participating in other researchers * Taking other dietary therapies, undergoing weight loss treatment * Vegetarian * Type 1 diabetes and type 2 diabetes using insulin

Locations (1)

Guangdong Provincial Hospital of Chinese Medicine

Guangzhou, Guangdong, China

Outcomes

Primary Outcomes

Change in eGFR (ml/min/1.73m2)

eGFR at final visit - eGFR at initial visit

Time frame: 12 weeks

Secondary Outcomes

Changes in body weight (Kilograms)

body weight at final visit - body weight at initial visit

Time frame: 12 weeks

Changes in waist circumference (cm)

waist circumference at final visit - waist circumference at initial visit

Time frame: 12 weeks

Change in body mass index (kg/m2)

body mass index at final visit - body mass index at initial visit

Time frame: 12 weeks

Changes in serum total cholesterol levels (mmol/L)

serum total cholesterol levels at final visit - serum total cholesterol levels at initial visit

Time frame: 12 weeks

Changes in serum low density lipoprotein cholesterol levels (mmol/L)

serum low density lipoprotein cholesterol levels at final visit - serum low density lipoprotein cholesterol levels at initial visit

Time frame: 12 weeks

Changes in serum triglyceride levels (mmol/L)

serum triglyceride levels at final visit - serum triglyceride levels at initial visit

Time frame: 12 weeks

Changes in serum high density lipoprotein cholesterol levels (mmol/L)

serum high density lipoprotein cholesterol levels at final visit - serum high density lipoprotein cholesterol levels at initial visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.